iLoF Secures $5m to Expand its Digital Library of Biomarkers 📰

Accelerating a new era of
personalised medicine

 

The intelligent platform for precise, patient-centric drug development

Our cloud-based library of optical fingerprints, powered by photonics and AI, provides non-invasive tracking, screening and stratification for drug discovery, adapted to each clinical trial needs.

Efficient. Flexible. Patient-centric.

Minimally Invasive

Requires only microlitres of blood

Agnostic

Allows for label free flexibility on targets

Rapid

Takes <10 seconds from start to finish

Low cost

Requires no consumables, only Light and AI

Featured By

Advancing Drug Discovery For Alzheimer's Disease

How can we help?

Our blood-based screening test stratifies patients for clinical trials, removing heterogeneity due to underlying pathophysiology, disease stage or degree of progression. The iLoF Platform offers:

40% cost savings
70% reduction of time spent on screenings
A non-invasive process for patient convenience
A pool of more qualified candidates, improving trial outcomes

Paving the way for personalised medicine

We believe the possibilities for the iLoF Platform are endless. Keeping Alzheimer’s as a leading focus, we are building out our virtual fingerprint library and plan to bring the power of this platform to other diseases

Alzheimer

Early and differential screening of dementia patients with Alzheimer’s Disease

COVID-19

Forecasting clinical outcomes and predicting severity of symptoms of Covid-19 patients

Ovarian Cancer

Stratifying cancer subtypes allowing for design and delivery of tailored treatments

Investors and Partners

Awards

GET IN TOUCH

United Kingdom

Unit 6 Queens Yard, White Post Lane
E9 5EN London

(+44) 01865 679064

Portugal

Medical Research Center
R. Dr. Plácido da Costa
4200-450 Porto

(+351) 220 426 664

info@ilof.tech

Privacy Policy